Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases

被引:18
作者
Hua, Fang [1 ]
Shi, Lingli [1 ]
Zhou, Peng [2 ,3 ]
机构
[1] Anhui Xinhua Univ, Pharm Sch, Hefei 230088, Peoples R China
[2] Anhui Univ Chinese Med, Sch Integrated Chinese & Western Med, Hefei 230012, Peoples R China
[3] Anhui Acad Chinese Med, Inst Integrated Chinese & Western Med, Hefei 230012, Peoples R China
基金
中国国家自然科学基金;
关键词
Phenols; Terpenoids; NLRP3; inflammasome; Cardiovascular diseases; NF-KAPPA-B; SIGNALING PATHWAY; MYOCARDIAL-INFARCTION; FERULIC ACID; INJURY; ACTIVATION; TRIPTOLIDE; POLYDATIN; CELASTROL; ORIDONIN;
D O I
10.1007/s10787-021-00918-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inflammatory infiltration has been implicated in the pathogenesis of cardiovascular diseases (CVDs). The NLRP3 inflammasome is involved in the development of several types of CVDs, including myocardial infarction, myocardial ischemia-reperfusion damage, heart failure, atrial fibrillation, and hypertension. Inhibiting the activity of NLRP3 inflammasome can inhibit the progress of CVDs. However, there is no NLRP3 inflammasome inhibitor in clinic, and it is very important to find a safe and effective NLRP3 inhibitor. Phenols and terpenoids are naturally natural products that have many anti-inflammatory effects in CVDs by modulating the NLRP3 inflammatory pathway. Thus, 20 natural products from phenols and terpenoids for the treatment of cardiovascular disease based on the inhibition of NLRP3 inflammasome were summarized and screened. Docking results showed salvianolic acid B and ellagic acid in phenols, and oridonin and triptolide in terpenoids had a better binding activity with NLRP3, which can provide theoretical support for finding novel NLRP3 inflammasome inhibitors or lead compounds in the future.
引用
收藏
页码:137 / 147
页数:11
相关论文
共 50 条
  • [1] Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases
    Fang Hua
    Lingli Shi
    Peng Zhou
    Inflammopharmacology, 2022, 30 : 137 - 147
  • [2] Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases
    Liu, Dongling
    Zeng, Xiang
    Li, Xiao
    Mehta, Jawahar L.
    Wang, Xianwei
    BASIC RESEARCH IN CARDIOLOGY, 2018, 113 (01)
  • [3] NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
    Mezzaroma, Eleonora
    Abbate, Antonio
    Toldo, Stefano
    MOLECULES, 2021, 26 (04):
  • [4] Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
    Ding, Nan
    Wei, Bo
    Fu, Xiaohui
    Wang, Chuan
    Wu, Yimou
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [5] Medicinal plants and bioactive natural products as inhibitors of NLRP3 inflammasome
    Bagherniya, Mohammad
    Khedmatgozar, Hamed
    Fakheran, Omid
    Xu, Suowen
    Johnston, Thomas P.
    Sahebkar, Amirhossein
    PHYTOTHERAPY RESEARCH, 2021, 35 (09) : 4804 - 4833
  • [6] NLRP3 inflammasome in cardiovascular diseases: an update
    Mo, Binhai
    Ding, Yudi
    Ji, Qingwei
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [7] NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications
    Pellegrini, Carolina
    Martelli, Alma
    Antonioli, Luca
    Fornai, Matteo
    Blandizzi, Corrado
    Calderone, Vincenzo
    MEDICINAL RESEARCH REVIEWS, 2021, 41 (04) : 1883 - 1926
  • [8] NLRP3 Inflammasome and Its Central Role in the Cardiovascular Diseases
    Tong, Yeqing
    Wang, Zhihong
    Cai, Li
    Lin, Liangqiang
    Liu, Jiafa
    Cheng, Jinquan
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2020, 2020
  • [9] NLRP3 inflammasome: The rising star in cardiovascular diseases
    Zheng, Yidan
    Xu, Li
    Dong, Nianguo
    Li, Fei
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [10] NLRP3 Inflammasome and Inflammatory Diseases
    Wang, Zheng
    Zhang, Simei
    Xiao, Ying
    Zhang, Wunai
    Wu, Shuai
    Qin, Tao
    Yue, Yangyang
    Qian, Weikun
    Li, Li
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2020, 2020